Our business model
The company will follow a highly virtual business model, outsourcing most validation and manufacturing activities to expedite the development of its first products and reduce capital requirements. Given the magnitude of the initial investment required, the sources of financing will come from more or less specialized private investment funds, as well as public investment and subsidies.
Limnopharma’s main objectives are:
- The manufacture of the drug from the active ingredients.
- Preclinical non-regulatory and regulatory validation.
- Approval for the clinical phases and the completion of phases I and/or I and II.
At this validation point, Limnopharma will seek opportunities to partially or totally sub-license the rights to the development and marketing of its products to large multinational pharmaceutical companies with a significant presence in the ophthalmology market.
In this way, it will take advantage of its experience and capacity in clinical trials, regulatory approval and manufacturing, as well as its distribution networks to introduce the product on the market, etc. The company’s revenue stream will consist of sub-license fees, payments by development, regulatory and marketing milestones, and ongoing royalties from drug sales.